Business Standard

India's TB programme: Low cost generics of J&J's MDR-TB drug on the anvil

Indian Patent Office's decision on J&J's bedaquiline came on the eve of World Tuberculosis Day, marked on March 24 every year, to raise public awareness & to boost efforts to end the TB epidemic

tuberculosis
Premium

Sohini Das Mumbai
India’s tuberculosis eradication programme is set for a boost after the Indian Patent Office rejected the application of American pharma giant Johnson & Johnson to extend its monopoly on a key TB drug – bedaquiline, which is set to expire in July. The drug is considered a key medication against multi-drug resistant TB.

The decision that came on the eve of World Tuberculosis Day - marked on March 24 every year - is going to bring smiles on the faces of TB patients in the country which reported 2.14 million TB patients in 2021, 18 per cent more than the

Don't miss the most important news and views of the day. Get them on our Telegram channel

First Published: Mar 24 2023 | 11:16 AM IST

Explore News

To read the full story, subscribe to BS Premium now, at just Rs 249/ month.

Key stories on business-standard.com are available only to BS Premium subscribers.

Register to read more on Business-Standard.com